Aroa Soriano Fernandez (Aroa Soriano)

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 11

Top Venues

Vall d'Hebron Institut de Recerca

Universitat de Barcelona (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Vall d'Hebron Institut de Recerca Feb 15 2012

Spain

Senior Researcher :: Translational Research in in Children and Adolescent Cancer

Institut d'Investigacio Biomedica de Bellvitge

Spain

Postdoctoral Researcher :: Neuropharmacology and Pain Research Gruop

Education History

Universitat de Barcelona

Spain

PHD :: Biochemistry and Molecular Biology

Universitat de Barcelona

Spain

BSC

Publications

Catherine Murphy, Laura Devis-Jauregui, Ronja Struck, Ariadna Boloix, Ciara Gallagher, Cian Gavin, Federica Cottone, Aroa Soriano Fernandez, Stephen Madden, Josep Roma, Miguel F Segura, Olga Piskareva
In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma. PloS one 19 (5) (2024)
Catherine Murphy, Laura Devis-Jauregui, Ronja Struck, Ariadna Boloix, Ciara Gallagher, Cian Gavin, Federica Cottone, Aroa Soriano Fernandez, Stephen Madden, Josep Roma, Miguel F Segura, Olga Piskareva
In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma. PloS one 19 (5) (2024)
Catherine Murphy, Laura Devis-Jauregui, Ronja Struck, Ariadna Boloix, Ciara Gallagher, Cian Gavin, Federica Cottone, Aroa Soriano Fernandez, Stephen Madden, Josep Roma, Miguel F Segura, Olga Piskareva
In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma. PloS one 19 (5) (2024)
Carlos Jiménez, Roberta Antonelli, Mariona Nadal-Ribelles, Laura Devis-Jauregui, Pablo Latorre, Carme Solé, Marc Masanas, Adrià Molero-Valenzuela, Aroa Soriano Fernandez, Josep Sánchez de Toledo, David Llobet-Navàs, Josep Roma, Francesc Posas, Eulalia de Nadal, Soledad Gallego Melcon, Lucas Moreno, Miguel F Segura
Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program. Molecular cancer 21 (1) (2022)
Clara Alcon, Fernando Martín Silva, Estela Prada, Jaume Mora, Aroa Soriano Fernandez, Gabriela Guillén Burrieza, Soledad Gallego Melcon, Josep Roma, Josep Samitier, Alberto Villanueva, Joan Montero
MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment. Cell death discovery 8 (1) (2022)
Marta Pérez-Hernández, Cristina Cuscó, Cristina Benítez-García, Joaquin Bonelli, Marina Nuevo-Fonoll, Aroa Soriano Fernandez, David Martínez-García, Alain Arias-Betancur, María García-Valverde, Miguel F Segura, Roberto Quesada, Josep Rocas, Vanessa Soto-Cerrato, Ricardo Pérez Tomás
Multi-Smart and Scalable Bioligands-Free Nanomedical Platform for Intratumorally Targeted Tambjamine Delivery, a Difficult to Administrate Highly Cytotoxic Drug. Biomedicines 9 (5) (2021)
Ariadna Boloix, Natalia Feiner-Gracia, Mariana Köber, Javier Repetto, Rosa Pascarella, Aroa Soriano Fernandez, Marc Masanas, Nathaly Segovia, Guillem Vargas-Nadal, Josep Merlo-Mas, Dganit Danino, Inbal Abutbul-Ionita, Laia Foradada, Josep Roma, Alba Córdoba, Santi Sala, Josep Sánchez de Toledo, Soledad Gallego Melcon, Jaume Veciana, Lorenzo Albertazzi, Miguel F Segura, Nora Ventosa
Engineering pH-Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics. Small (Weinheim an der Bergstrasse, Germany) (2021)
Carlos Jiménez, Roberta Antonelli, Marc Masanas, Aroa Soriano Fernandez, Laura Devis-Jauregui, Jessica Camacho, Ainara Magdaleno, Gabriela Guillén, Raquel Hladun, Luz Jubierre, Josep Roma, David Llobet-Navàs, Josep Sánchez de Toledo, Lucas Moreno, Soledad Gallego Melcon, Miguel F Segura
Neuronal Differentiation-Related Epigenetic Regulator ZRF1 Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro. Cancers 13 (19) (2021)
Laia París-Coderch, Aroa Soriano Fernandez, Carlos Jiménez, Tatiana Erazo, Pau Muñoz-Guardiola, Marc Masanas, Roberta Antonelli, Ariadna Boloix, José Alfón, Héctor Pérez-Montoyo, Marc Yeste-Velasco, Carles Domènech, Josep Roma, Josep Sánchez de Toledo, Lucas Moreno, Jose Miguel Lizcano, Soledad Gallego Melcon, Miguel F Segura
The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis. Cell death & disease 11 (9) (2020)
Clara Alcon, Albert Manzano-Muñoz, Estela Prada, Jaume Mora, Aroa Soriano Fernandez, Gabriela Guillén Burrieza, Soledad Gallego Melcon, Josep Roma, Josep Samitier, Alberto Villanueva, Joan Montero
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance. Cell death & disease 11 (8) (2020)
Andrea Feliciano, Yoelsis Garcia-Mayea, Luz Jubierre, Cristina Mir, Manuela Hummel, Josep Castellvi, Javier Hernández-Losa, Rosanna Paciucci, Irene Sansano, Yilin Sun, Santiago Ramón Y Cajal, Hiroshi Kondon, Aroa Soriano Fernandez, Miguel F Segura, Alex Lyakhovich, Matilde E LLeonart
miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer. Cell death & disease 8 (10) (2017)

Aroa Soriano Fernandez.css-eqlu8i{font-size:small;padding-left:4px;} (Aroa Soriano)

Publication Activity (10 Years)

Top Topics

Top Venues

Aroa Soriano Fernandez (Aroa Soriano)